Business Context and Reporting Period
Company: Manhattan Pharmaceuticals, Inc. (Note: Metadata listed "TG THERAPEUTICS, INC." but the filing text identifies the registrant as Manhattan Pharmaceuticals, Inc.)
Reporting Period: Fiscal year ended December 31, 2009
Business Model: A development-stage biopharmaceutical company focused on acquiring, developing, and commercializing innovative treatments for underserved patient populations. The company has no product revenues and relies on financing and joint ventures to fund operations.
Key Portfolio:
- Hedrin: Non-insecticide treatment for head lice (developed via a 50/50 Joint Venture with Nordic Biotech).
- AST-726: Nasal spray for Vitamin B12 deficiency (acquired via merger with Ariston Pharmaceuticals in March 2010).
- AST-915: Oral treatment for essential tremor (acquired via Ariston merger).
- Topical GEL: Potential OTC treatment for mild psoriasis.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,793,285) | $(4,268,859) |
| Cash and Cash Equivalents (Year End) | $17,996 | $106,023 |
| Net Cash Used in Operating Activities | $(1,049,799) | $(4,444,009) |
| Total Current Liabilities | $2,532,207 | $1,486,368 |
| Working Capital Deficit | $(2,268,482) | $(612,128) |
| Accumulated Deficit (Inception to 2009) | $(61,933,435) | $(59,267,928) |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately 35% (from $4.27M to $2.79M) primarily due to a significant reduction in Research and Development (R&D) expenses ($1.76M decrease) and General and Administrative (G&A) expenses ($0.88M decrease).
- R&D Expenses: Dropped from $1.80M in 2008 to $40,000 in 2009. The company ceased active development of most internal products due to lack of funds, shifting Hedrin development costs to the Hedrin Joint Venture.
- Other Income/(Expense): Turned from a net income of $144,000 in 2008 to a net expense of $(1.02M) in 2009. This was driven by a $(560,000) change in the fair value of a derivative liability and increased interest/amortization expenses on notes payable.
- Liquidity: Cash reserves declined significantly from $106,000 to $18,000. Current liabilities increased by $1.05M, largely due to the recognition of derivative liabilities and secured notes payable.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning: The independent auditors have included an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and an accumulated deficit.
Outlook and Guidance:
- Management believes capital raised in March 2010 (approx. $2.2M net) is sufficient to fund operations through 2010.
- Additional equity or debt financing will be required to sustain operations into 2011 and to complete product development.
- No product revenues are expected prior to December 31, 2010.
Material Subsequent Events:
- Ariston Merger: On March 8, 2010, the company merged with Ariston Pharmaceuticals, Inc., acquiring AST-726 and AST-915. Consideration included 7.06M shares plus up to 24.7M milestone shares.
- Equity Financing: In March 2010, the company raised approximately $2.55M gross proceeds via a private placement of units (common stock and warrants).
- Hedrin JV Capital Call: Nordic Biotech contributed $500,000 to the Hedrin JV in January 2010. Manhattan could not match this contribution, resulting in dilution of its ownership in the JV from 50% to 47.62%.
Risks:
- Dependence on third-party financing and joint ventures.
- Regulatory approval risks for Hedrin (Class III medical device requiring PMA) and AST-726.
- Significant dilution potential from anti-dilution provisions in Nordic's put/warrant rights and convertible notes.
- Stock price volatility and limited liquidity (traded on OTC Bulletin Board).
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the March 2010 financing ($2.2M net) to cover operating expenses through 2010, given the history of negative cash flow.
- Dilution Impact: Assess the potential dilution from the Ariston merger (milestone shares and convertible notes) and the anti-dilution adjustments to Nordic's put/warrant rights triggered by the March 2010 financing.
- Hedrin JV Ownership: Confirm the current ownership split in the Hedrin Joint Venture (47.62% Manhattan / 52.38% Nordic) and the implications for future profit sharing and control.
- Regulatory Pathways: Review the specific FDA requirements for Hedrin (Class III PMA) and AST-726 (505(b)(2) NDA) to understand the timeline and cost to commercialization.
- Debt Obligations: Examine the terms of the Secured 12% Notes and Convertible 12% Notes, including interest rates, maturity dates, and collateral (pledge of assets excluding Hedrin JV interest).